211 related articles for article (PubMed ID: 37014824)
1. Arterial and Venous Thromboembolism in ALK-Rearrangement-Positive Non-small Cell Lung Cancer: A Population-Based Cohort Study.
Icht O; Leader A; Batat E; Yosef L; Shochat T; Goldstein DA; Dudnik E; Spectre G; Raanani P; Hammerman A; Zer A
Oncologist; 2023 Jun; 28(6):e391-e396. PubMed ID: 37014824
[TBL] [Abstract][Full Text] [Related]
2. Impact of ALK Rearrangement on Venous and Arterial Thrombotic Risk in NSCLC.
Al-Samkari H; Leiva O; Dagogo-Jack I; Shaw A; Lennerz J; Iafrate AJ; Bendapudi PK; Connors JM
J Thorac Oncol; 2020 Sep; 15(9):1497-1506. PubMed ID: 32437899
[TBL] [Abstract][Full Text] [Related]
3. Association of ALK rearrangement and risk of venous thromboembolism in patients with non-small cell lung cancer: A prospective cohort study.
Dou F; Zhang Y; Yi J; Zhu M; Zhang S; Zhang D; Zhang Y
Thromb Res; 2020 Feb; 186():36-41. PubMed ID: 31864154
[TBL] [Abstract][Full Text] [Related]
4. ALK-Rearranged Non-Small-Cell Lung Cancer Is Associated With a High Rate of Venous Thromboembolism.
Zer A; Moskovitz M; Hwang DM; Hershko-Klement A; Fridel L; Korpanty GJ; Dudnik E; Peled N; Shochat T; Leighl NB; Liu G; Feld R; Burkes R; Wollner M; Tsao MS; Shepherd FA
Clin Lung Cancer; 2017 Mar; 18(2):156-161. PubMed ID: 27913214
[TBL] [Abstract][Full Text] [Related]
5. Risk factors and prognostic impact of venous thromboembolism in Asian patients with non-small cell lung cancer.
Lee YG; Kim I; Lee E; Bang SM; Kang CH; Kim YT; Kim HJ; Wu HG; Kim YW; Kim TM; Lee KW; Lee SH; Kim DW; Heo DS
Thromb Haemost; 2014 Jun; 111(6):1112-20. PubMed ID: 24477503
[TBL] [Abstract][Full Text] [Related]
6. Risk of thromboembolism in patients with ALK- and EGFR-mutant lung cancer: A cohort study.
Roopkumar J; Poudel SK; Gervaso L; Reddy CA; Velcheti V; Pennell NA; McCrae KR; Khorana AA
J Thromb Haemost; 2021 Mar; 19(3):822-829. PubMed ID: 33314597
[TBL] [Abstract][Full Text] [Related]
7. Thromboembolism in ALK+ and ROS1+ NSCLC patients: A systematic review and meta-analysis.
Zhu VW; Zhao JJ; Gao Y; Syn NL; Zhang SS; Ou SI; Bauer KA; Nagasaka M
Lung Cancer; 2021 Jul; 157():147-155. PubMed ID: 34049720
[TBL] [Abstract][Full Text] [Related]
8. ROS1-rearranged Non-small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS).
Chiari R; Ricciuti B; Landi L; Morelli AM; Delmonte A; Spitaleri G; Cortinovis DL; Lamberti G; Facchinetti F; Pilotto S; Verusio C; Chella A; Bonanno L; Galetta D; Cappuzzo F
Clin Lung Cancer; 2020 Jan; 21(1):15-20. PubMed ID: 31607443
[TBL] [Abstract][Full Text] [Related]
9. Risk of thromboembolism in non-small-cell lung cancers patients with different oncogenic drivers, including ROS1, ALK, and EGFR mutations.
Wang HY; Wu SG; Lin YT; Chen CY; Shih JY
ESMO Open; 2022 Dec; 7(6):100742. PubMed ID: 36493600
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations.
Lou NN; Zhang XC; Chen HJ; Zhou Q; Yan LX; Xie Z; Su J; Chen ZH; Tu HY; Yan HH; Wang Z; Xu CR; Jiang BY; Wang BC; Bai XY; Zhong WZ; Wu YL; Yang JJ
Oncotarget; 2016 Oct; 7(40):65185-65195. PubMed ID: 27533086
[TBL] [Abstract][Full Text] [Related]
11. Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors.
Icht O; Darzi N; Shimony S; Jacobi O; Reinhorn D; Landman Y; Mutai R; Averbuch I; Shochat T; Spectre G; Raanani P; Rotem O; Dudnik E; Peled N; Zer A; Leader A
J Thromb Haemost; 2021 May; 19(5):1250-1258. PubMed ID: 33605020
[TBL] [Abstract][Full Text] [Related]
12. Common genetic driver mutation in NSCLC and their association with thromboembolic events: A retrospective study.
Lin M; Lu Y; Yu Q; Chen Z; Peng J; Cai X
Lung Cancer; 2022 Oct; 172():29-34. PubMed ID: 35986977
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
Qin K; Hou H; Liang Y; Zhang X
BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384
[TBL] [Abstract][Full Text] [Related]
14. Clinical features of Bim deletion polymorphism and its relation with crizotinib primary resistance in Chinese patients with ALK/ROS1 fusion-positive non-small cell lung cancer.
Zhang L; Jiang T; Li X; Wang Y; Zhao C; Zhao S; Xi L; Zhang S; Liu X; Jia Y; Yang H; Shi J; Su C; Ren S; Zhou C
Cancer; 2017 Aug; 123(15):2927-2935. PubMed ID: 28346673
[TBL] [Abstract][Full Text] [Related]
15. The incidence of venous thromboembolism among patients with primary lung cancer.
Chew HK; Davies AM; Wun T; Harvey D; Zhou H; White RH
J Thromb Haemost; 2008 Apr; 6(4):601-8. PubMed ID: 18208538
[TBL] [Abstract][Full Text] [Related]
16. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
Gettinger SN; Bazhenova LA; Langer CJ; Salgia R; Gold KA; Rosell R; Shaw AT; Weiss GJ; Tugnait M; Narasimhan NI; Dorer DJ; Kerstein D; Rivera VM; Clackson T; Haluska FG; Camidge DR
Lancet Oncol; 2016 Dec; 17(12):1683-1696. PubMed ID: 27836716
[TBL] [Abstract][Full Text] [Related]
17. High plasma levels of soluble P-Selectin and Factor VIII predict venous thromboembolism in non-small cell lung cancer patients: The Thrombo-Nsclc risk score.
Castellón Rubio VE; Segura PP; Muñoz A; Farré AL; Ruiz LC; Lorente JA
Thromb Res; 2020 Dec; 196():349-354. PubMed ID: 32977135
[TBL] [Abstract][Full Text] [Related]
18. Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.
Goto Y; Yamamoto N; Masters ET; Kikkawa H; Mardekian J; Wiltshire R; Togo K; Ohe Y
Adv Ther; 2020 Jul; 37(7):3311-3323. PubMed ID: 32472430
[TBL] [Abstract][Full Text] [Related]
19. Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.
Watanabe S; Hayashi H; Okamoto K; Fujiwara K; Hasegawa Y; Kaneda H; Tanaka K; Takeda M; Nakagawa K
Clin Lung Cancer; 2016 Nov; 17(6):528-534. PubMed ID: 27318655
[TBL] [Abstract][Full Text] [Related]
20. Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression.
Chen RL; Zhao J; Zhang XC; Lou NN; Chen HJ; Yang X; Su J; Xie Z; Zhou Q; Tu HY; Zhong WZ; Yan HH; Guo WB; Wu YL; Yang JJ
BMC Cancer; 2018 Nov; 18(1):1171. PubMed ID: 30477470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
